Microbes Engineered as Continuous Assembly Lines
▼ Summary
– Cauldron Ferm’s core continuous fermentation technology originated from the decades-long work of David and Polly McLennan, who aimed to produce affordable microbial protein for food.
– The company has transitioned from a small fee-for-service operation to a startup, raising a total of $19.75 million in funding, including a recent $13.25 million Series A2 round.
– Its “hyper fermentation” technology maintains microbes in a maximally productive state and can be adapted for use in existing batch fermentation facilities.
– The startup currently focuses on producing fats and proteins like whey for the food supply chain but plans to diversify into other biological products.
– CEO Michele Stansfield recognized the significant challenge and potential of continuous fermentation for synthetic biology, leading her to acquire the company’s assets and pivot its business model.
The story of Cauldron Ferm begins decades ago, not in a modern lab but with the persistent vision of David and Polly McLennan. Their goal was to address global hunger by producing protein from microbes, a concept they pursued for over forty years. The central challenge they faced was economic. Traditional batch fermentation, common in industries like brewing, is a stop-start process ill-suited for affordable food production. To make microbial protein viable, they needed a system that could operate continuously, turning living cells into efficient, uninterrupted assembly lines.
Michele Stansfield, who joined the McLennans’ operation in 2012 and is now co-founder and CEO, recognized the untapped potential. “We didn’t know what we had,” Stansfield admitted. She came to understand the significant technical hurdle of adapting continuous fermentation for synthetic biology applications. This realization prompted a strategic shift, transforming the small service operation into an ambitious startup. Stansfield led a seed funding round to acquire the company’s foundational intellectual property and physical assets.
This transformation has accelerated with new capital. Cauldron recently secured $13.25 million in a Series A2 financing round led by Main Sequence Ventures, with Horizons Ventures, NGS Super, and SOSV also participating. This follows a $6.5 million raise earlier in 2024. Stansfield states the capital will be used to deepen the company’s technology moat and advance its proprietary platform.
That platform, termed hyper fermentation, is designed to maintain microbes in a peak state of productivity. The system can be integrated into conventional batch fermentation infrastructure with targeted facility modifications. Cauldron’s clients provide their specialized microbial strains, and the company optimizes the growth environment,fine-tuning nutrients and conditions,to ensure consistent, high-yield output.
While the initial focus is on food ingredients like whey protein, which can integrate seamlessly into existing supply chains, Cauldron’s ambitions are broadening. “Sixty percent of all inputs to the global economy can be produced from biology,” Stansfield notes. “Food was where we started, but now we’re starting to really diversify.” The company’s core technology represents a foundational shift in bioproduction, moving from periodic batches to a steady, efficient flow of biologically derived materials.
(Source: TechCrunch)
